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Phe Involvement of Tumor Necrosis Factor-Related
poptosis-Inducing Ligand (TRAIL) in Atherosclerosis
oav Michowitz, MD,* Emil Goldstein, MD,* Arie Roth, MD,* Arnon Afek, MD,*
nastasia Abashidze, BSC,* Yanai Ben Gal, MD,† Gad Keren, MD, FACC,* Jacob George, MD*
el Aviv, Israel
OBJECTIVES Herein, we determined the significance of tumor necrosis factor (TNF)-related apoptosis-
inducing ligand (TRAIL) in atherosclerotic vascular disease.
BACKGROUND Inflammation is associated with the pathogenesis of atherosclerosis. The TNF-related
apoptosis-inducing ligand/APO-2L, a member of the TNF superfamily, has a role in
apoptosis induction and is recognized for its immunomodulatory properties.
METHODS Stable and vulnerable atherosclerotic human plaques and aortas from atherosclerotic mice
were assayed for the presence of TRAIL, and its inducibility was assayed by immunoblot and
real-time polymerase chain reaction on peripheral mononuclear cells incubated with oxidized
low-density lipoprotein (oxLDL). Enzyme-linked immunosorbent assay was used for the
determination of soluble TRAIL levels in atherosclerotic patients.
RESULTS Tumor necrosis factor-related apoptosis-inducing ligand is present in stable atherosclerotic
lesions, is increased in vulnerable plaques, and is found to colocalize with CD3 cells and
oxLDL. The TNF-related apoptosis-inducing ligand messenger ribonucleic acid (mRNA)
and protein expression was up-regulated in peripheral blood mononuclear cells after
incubation with oxLDL. Serum levels of soluble TRAIL but not TNF-alpha or Fas-ligand
were reduced significantly in patients with unstable angina as compared with patients with
stable atherosclerotic disease and healthy subjects. A negative correlation was demonstrated
between soluble TRAIL and C-reactive protein levels but not with levels of mRNA of
TRAIL in peripheral blood mononuclear cells.
CONCLUSIONS Tumor necrosis factor-related apoptosis-inducing ligand is expressed in plaque-infiltrating
CD3 cells and induced by oxLDL, whereas levels of soluble TRAIL are reduced in patients
with acute coronary syndromes and negatively correlate with C-reactive protein levels. These
results support a possible role for TRAIL in atherosclerosis. (J Am Coll Cardiol 2005;45:
ublished by Elsevier Inc. doi:10.1016/j.jacc.2004.12.0651018–24) © 2005 by the American College of Cardiology Foundation
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an recent years, accumulating data implicate inflammatory
rocesses in the pathogenesis of atherosclerosis and pheno-
ype transition of the plaque from stable to a vulnerable one
1–3). Atherosclerotic plaques are composed of a lipid core,
brous cap, and inflammatory infiltrates containing princi-
ally T cells and macrophages. Activated T lymphocytes
lay an important role in the initiation and progression of
therosclerosis (1–3). Several antigens are implicated in
-cell activation, the principal one of which is oxidized
ow-density lipoprotein (oxLDL) (3,4).
Acute coronary syndromes (ACS), including unstable
ngina and acute myocardial infarction, are caused predom-
nantly by the rupture of the fibrous cap overlying a
ulnerable coronary atherosclerotic plaque, with subsequent
latelet aggregation and thrombus formation. Inflammation
ppears to play a key factor in these events (5,6). Inflam-
atory markers such as C-reactive protein (CRP) and
nterleukin-6 were shown to correlate with coronary adverse
vents (1–3), whereas interleukin-10, which exhibits anti-
From the *Department of Cardiology and †Department of Cardiothoracic Surgery,
el Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel Aviv University,
el Aviv, Israel. Drs. Michowitz, Goldstein, Afek, Abashidze, Ben Gal, and George
ere involved in planning and experimentation. Drs. Michowitz and George wrote
he article. Dr. Keren was involved in the planning and writing of the article.t
Manuscript received October 15, 2004; revised manuscript received November 26,
004, accepted December 6, 2004.nflammatory properties, may have a protective role in
therosclerosis (7).
Tumor necrosis factor (TNF)-related apoptosis-inducing
igand (TRAIL)/APO-2L is a member of the TNF ligand
uperfamily (8,9). Its primarily recognized biologic activity
s induction of apoptosis in cancer cells through its interac-
ion with death receptors (DR4 and/or DR5) on trans-
ormed or infected cells. Although TRAIL is not constitu-
ively expressed on the surface of inactivated cells of the
mmune system, its expression is up-regulated in response to
timulation with cytokines (10). Moreover, TRAIL has
een demonstrated to inhibit autoantigen-specific T cells,
uggesting it may suppress autoimmune responses (11).
Recent studies have reported that TRAIL confers
ndothelial cell protection from apoptosis and prolifera-
ion by the Akt and extracellular signal-regulated kinase
athways (12,13). These results are complemented by
bservations showing that the addition of TRAIL to
rimary human endothelial cells increased the phosphor-
lation of endothelial nitric oxide synthase activity, with
ubsequent nitric oxide synthesis (13). In view of the key
ole of T cells and endothelial cells in the pathogenesis of
theroma and plaque destabilization, we reasoned that
RAIL could be expressed within atherosclerotic plaques
nd may be associated with immune-modulating proper-
ies that could prove protective.
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aterials, reagents, and antibodies. Oxidized low-density
ipoprotein was prepared as previously described (14). Ly-
ophosphatidylcholine (LPC), an active derivative of ox-
DL, was purchased from Sigma (St. Louis, Missouri).
Antibodies used for immunohistochemistry and Western
lotting consisted of rabbit polyclonal anti-human TRAIL
ntibodies that are reactive with the amino acids 25-281 at
he carboxy terminus of TRAIL (Santa Cruz Biotechnol-
gy, Santa Cruz, California) and are cross-reactive with
urine TRAIL. Anti-CD3 antibodies were from DAKO
Carpinteria, California). Anti-oxLDL antibodies were ei-
her polyclonal, prepared as previously described (14), or
ouse anti-Apo B100 IgG (ICN Pharmaceuticals Inc.,
urora, Ohio).
mmunoblotting for detection of TRAIL in human and
urine plaques. Human atherosclerotic plaques from ca-
otid endarterectomy samples (n  8) and sections of left
nternal mammary arteries (n 7) obtained during coronary
rtery bypass graft operations were kept frozen at 80°C
fter washing them from surrounding the tissue and blood
lots. For comparison of stable and unstable (vulnerable)
esions with regard to TRAIL expression, we obtained
amples of plaques removed electively from patients with
eripheral vascular disease (stable plaques; n  5) and from
atients with ACS that underwent rheolytic therapy with
he Angiojet system (n  4; Possis Medical, Minneapolis,
innesota). This technique allows for a suction force that
isintegrates and removes thrombus and plaque content
rom culprit arteries in patients with ACS. The generated
uid was centrifuged, red cells were lysed, and plaque
ontent was homogenized and frozen at 80°C until
lotting was performed. These plaques are considered to be
ulnerable because of their association with the thrombus
nd the respective clinical picture. On the day of immuno-
lotting, samples were defrosted at room temperature,
ashed with phosphate-buffered saline, and homogenized
n a lysis buffer. After centrifugation, the supernatant were
pplied on a 10% acrylamide sodium dodecyl sulfate gel
Abbreviations and Acronyms
ACS  acute coronary syndrome
CRP  C-reactive protein
hsCRP  high-sensitivity C-reactive protein
LPC  lysophosphatidylcholine
oxLDL  oxidized low-density lipoprotein
mRNA  messenger ribonucleic acid
NCA  normal coronary arteries
PBMCs  peripheral blood mononuclear cells
RT-PCR  reverse-transcription polymerase chain
reaction
TNF  tumor necrosis factor
TRAIL  tumor necrosis factor-related apoptosis-
inducing ligandnder reduced conditions, transferred to nitrocellulose pa- fer, and probed with anti-TRAIL antibodies (Santa Cruz
iotechnology). The same procedure was applied to athero-
clerotic aortas of 10-month-old ApoE knockout mice and
hose of age-matched C57BL/6 mice (used as control
onatherosclerotic aortas).
mmunohistochemical study of human atherosclerotic
esions. Five-micrometer thick frozen sections of human
arotid plaques were sectioned. After fixation and blocking
ith nonimmune serum, we added the primary antibodies
anti-TRAIL antibodies, anti-CD3 antibodies, and anti-
xLDL antibodies) for 1 h at room temperature. After
ashing, biotinylated affinity-purified secondary antibodies
ere added. The slides were then incubated with 0.3%
2O2, followed by additional rinses and incubation
treptavidin-peroxidase conjugate (Jackson Laboratories,
ar Harbor, Maine) for 30 min. The slides were developed
ith 3-amino-9 ethylcarbazole substrate (DAKO) for 15
in and counterstained with hematoxylin.
atients. Three group of subjects were selected. Group 1
omprised patients with ACS that were admitted in the
ntensive coronary care unit (n  40), group 2 comprised
atients with stable angina pectoris with angiographically
ocumented atherosclerosis (n  28), and group 3 com-
rised subjects with normal coronary arteries (NCA) as
etermined by angiography (n  20). Acute coronary
yndrome in all patients was defined as chest pain accom-
anied by definite ischemic electrocardiographic changes
ST-segment changes and/or T-wave inversions). Myocar-
ial infarction was diagnosed if either: 1) elevation of
roponin I (0.8 ng/ml) or creatine kinase-myocardial band
), or 2) definite (2 mm) ST-segment elevations in at
east two consecutive leads also was present.
solation of peripheral blood mononuclear cells
PBMCs). Peripheral blood mononuclear cells were iso-
ated from 30 ml of freshly drawn heparinized blood using
sopaque-Ficoll (Amersham Biosciences, Buckinghamshire,
nited Kingdom) gradient centrifugation. To eliminate
ontamination by monocyte/macrophage cells were seeded
n plastic plates for 4 h and nonadherent cells were collected
nd subjected for further assays.
etection of TRAIL in oxLDL/LPC-primed PBMCs by
estern blot. Peripheral blood mononuclear cells from
ealthy volunteers were suspended in RPMI 1640 plus
ntibiotics (50 mg/ml of penicillin and streptomycin),
-glutamine, and 10% fetal calf serum. The cells were
ultured in six-well plates and incubated for 24 h at 37°C
ith oxLDL (50 g/ml), LPC (50 and 100 mol/l), or
edium. The cells were harvested, washed with phosphate-
uffered saline, and lysed with a lysis buffer. We then
nalyzed them by western blot using anti-TRAIL antibod-
es (Santa Cruz Biotechnology) as described previously.
eal-time quantitative reverse-transcription polymerase
hain reaction (RT-PCR) for the detection of TRAIL
RNA. Total ribonucleic acid from the PBMCs of ran-
om patients from the three groups (nine from group 1, six
rom group 2, and five from group 3) was isolated using
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TRAIL and Atherosclerosis April 5, 2005:1018–24Neasy kit (Qiagen, Hilden, Germany). Reverse transcrip-
ion to complementary deoxyribonucleic acid was performed
ith random hexamers using the TaqMan reverse transcrip-
ion reagents according to manufacturer’s instructions.
eal-time quantitative RT-PCR was performed on an
BI Prism 7700 sequence detection system (Applied Bio-
ystems, Cheshire, United Kingdom). The sequence of the
rimers used was as follows: TRAIL forward, 5=-
AGAGGAAGAAGCAACACATTCTCT-3=; TRAIL
everse, 5=-TGATGATTCCCAGGAGTTTATTTTG-
=; beta-actin forward, 5=-TGAGCGCGGCTACAGC-
T-3=; beta-actin reverse, 5=-TCCTTAATGTCACGC-
CGATTT-3=.
nzyme-linked immunosorbent assay (ELISA) for the
etection of soluble TRAIL, Fas-ligand (sFasL), and
NF-alpha levels. Blood samples were taken within 48 h
f hospital admission in patients with ACS. After separa-
ion according to standard procedures, serum samples were
ept at 80°C until further testing. Blood samples from
atients in groups 2 and 3 were obtained in the ambulatory
linic. Quantitative determination of soluble TRAIL was
erformed using a sandwich ELISA kit with a detection
imit of 20 pg/ml according to the manufacturer’s protocol
BioSource International Inc., Camarillo, California).
Serum concentrations of sFasL were determined in du-
licate with commercially available ELISA kits (Diaclone
esearch, Besancon, France). The sensitivity for detection
f sFasL was 12 pg/ml. Serum TNF-alpha levels were
etermined using ELISA according to the manufacturer’s
ecommendations (R&D Systems, Minneapolis, Minne-
ota). The sensitivity of the ELISA was 80 pg/ml for
NF-alpha.
igh-sensitivity CRP (hsCRP) concentrations. The as-
ay for hsCRP was conducted according to manufacturer’s
nstructions (Dade Behring Inc., Deerfield, Illinois). Briefly,
he principle of the method includes using polystyrene
articles coated with monoclonal antibodies to CRP. These
articles agglutinate with CRP. The CRP level was deter-
ined according to the intensity of the scattered light in the
ephelometer compared with standards of a known
oncentration.
tatistical analysis. A comparison among the three differ-
nt groups of patients was performed by one-way analysis of
ariance for continuous variables and chi-square test for
ategorical variables. The Fisher exact test was used for
ategorical variables when the number of observations per
ell was expected to be 5. The Dunnett multiple compar-
son procedure and logistic regression models were used for
air-wise comparisons between patients with ACS and the
wo other groups.
Because of the small number of patients tested for the
mount of mRNA of TRAIL in PBMCs, the comparison
mong the three different groups regarding this variable was
erformed with the Kruskal-Wallis nonparametric analysis
f variance test.
Linear regression model was applied to test the associa-
e
eion among the three groups of patients and soluble TRAIL
evels after adjusting for possible confounding variables. All
tatistically significant variables on a univariate analysis (p
.05) were candidates for the regression equation; several
ariable selection methods were then used (all variables,
orward selection, backward elimination). Statistical signif-
cance was defined as a value of p  0.05. The SAS system
.01 software for Windows (SAS Institute, Cary, North
arolina) was used for all calculations.
ESULTS
sing Western blotting, we observed TRAIL protein ex-
ression in human atherosclerotic plaques, whereas control
rteries (left internal mammary arteries) representing non-
esional vessels exhibited significantly lower TRAIL expres-
ion (Fig. 1A). We then compared the expression of
RAIL in vulnerable plaques known to reside in patients
ith ACS to stable plaques removed from the femoral
rteries on elective surgery (Fig. 1B). We found that
ulnerable plaques contain a significantly higher content of
RAIL as compared with stable plaques. Aiming to con-
rm the presence of TRAIL in an additional species, we
xplored and detected TRAIL expression in the atheroscle-
igure 1. (A) Shown is the expression of tumor necrosis factor-related
poptosis-inducing ligand (TRAIL) in atherosclerotic and normal vessels
etected by Western blotting in sections of human atherosclerotic plaques
nd nonatherosclerotic arteries (left internal mammary arteries [LIMA])
nd compared with the expression of the housekeeping protein beta-
ubulin. (B) Shown is the expression of TRAIL in vulnerable and stable
therosclerotic plaques. Stable plaques removed from femoral arteries (a),
nd representative vulnerable plaques (b and c) were removed by suction
fter the application of a rheolytic device from culprit arteries. The
xpression of TRAIL was assayed by Western blotting and compared with
xpression of beta tubulin. Densitometric analysis is shown in the graph.
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April 5, 2005:1018–24 TRAIL and Atherosclerosisotic aortas of 10-month-old apo-E–deficient mice as com-
ared with control C57BL/6 littermates of similar genetic
ackground exhibiting no atherosclerosis (data not shown).
Next, we aimed to define the nature of cells expressing
RAIL protein and to determine its possible colocalization
ith oxLDL. Indeed, TRAIL was expressed in carotid ath-
rosclerotic plaques within CD3-positive cells, and its expres-
ion was abundant in areas that stained positive for oxLDL
Fig. 2). The principal regions in which TRAIL-positive cells
ere evident were the interface regions between the lipid core
nd the media and within the shoulder regions of the plaques
here lymphocytes are predominantly known to reside.
Because oxLDL was found to colocalize with TRAIL, we
easoned that it could play a causative role by inducing the
xpression of the latter. Indeed, incubation of PBMCs with
xLDL but not with its active derivative, LPC, up-
egulated expression of TRAIL messenger ribonucleic acid
mRNA) (Fig. 3A) and protein (Fig. 3B) in these cells.
nduction of TRAIL mRNA was evident and peaked
lready 6 h after incubation with 50 g/ml of oxLDL.
After having confirmed the presence of TRAIL and its
nducibility in atherosclerotic plaques, we went on to test
he functional significance of this protein. For this purpose,
e assayed serum levels of soluble TRAIL in the sera of
hree groups of patients. Group 1 consisted of patients with
CS (n  40), group 2 consisted of patients with stable
igure 2. The presence and immunolocalization of tumor necrosis factor
ections from human atherosclerotic plaque where TRAIL (lower right p
upper left panel) represent the corresponding primary antibody used.
iscriminates the fibrous cap from the lipid core.therosclerotic disease (n  28), and group 3 consisted of subjects with angiographically confirmed normal coronary
rteries (n  20). To exclude a confounding effect of
therosclerotic burden on TRAIL levels, we matched the
atients with ACS and those with stable angina for coronary
rtery affliction. This resulted in two groups with a similar
umber of afflicted atherosclerotic coronary arteries. Base-
ine clinical characteristics of the three subject groups are
resented in Table 1.
We found that levels of soluble TRAIL were significantly
ower in patients with ACS as compared with both other
roups of patients (p  0.0001, compared with stable
therosclerosis patients; mean difference, 344 pg/ml, 95%
onfidence interval 191.8 to 496.4, and when compared
ith subjects with NCA; mean difference, 398.5 pg/ml,
5% confidence interval 224.2 to 567.7) (Fig. 4A). This
ifference remained statistically significant, even after using
ultiple linear regression analysis and including all variables
hat were significant on univariate analysis. No difference
as found in soluble TRAIL levels between patients with
table atherosclerotic coronary disease and patients with
CA (p  0.56), although the mean level was slightly
igher in the latter group. In group 1 there were 24 patients
ith acute myocardial infarction and 16 with unstable
ngina. No difference in soluble TRAIL levels existed
etween these two subgroups (p  0.51).
Levels of sFasL did not differ between patients with
d apoptosis-inducing ligand (TRAIL) in human atheroma. Consecutive
, oxidized low-density lipoprotein (oxLDL) (lower left panel), and CD3
pper right panel is a Masson’s trichrome stain of fibrotic tissues and-relate
anel)table angina (34.2  7.3 pg/ml) and unstable angina (38.6

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TRAIL and Atherosclerosis April 5, 2005:1018–245.6 pg/ml). No detectable levels were noted in the
ultured medium of PMBCs. Similarly, no significant
ifferences were evident with regard to serum levels of
NF-alpha: 12  3.5 pg/ml in the stable angina patients
ersus 13.4  4.5 pg/ml in the unstable angina patients.
Because CRP is associated with high likelihood of ad-
erse events in patients with atherosclerosis and also has
een suggested to play a detrimental role in plaque forma-
ion, we evaluated the correlation between TRAIL protein
evels and CRP concentrations. Interestingly, we found a
egative correlation between CRP concentrations and sol-
ble TRAIL levels (r20.26; p 0.016). The expression
f TRAIL mRNA in PBMCs assayed by real-time RT-
igure 3. Tumor necrosis factor-related apoptosis-inducing ligand
TRAIL) inducibility by oxidized low-density lipoprotein (oxLDL) and
ysophosphatidylcholine (LPC). (A) Oxidized low-density lipoprotein was
ncubated with peripheral blood mononuclear cells for the indicated time
oints. Ribonucleic acid was extracted as described in the Methods section,
nd real-time reverse-transcription polymerase chain reaction was used to
nvestigate the inducibility of messenger ribonucleic acid for TRAIL.
esults are expressed after normalization with beta-actin mRNA as an
-fold increase from baseline. (B) For detection of the TRAIL protein,
xLDL (50 g/ml) or LPC (at the indicated concentrations) were
ncubated with peripheral blood mononuclear cells, after which cell lysates
ere subjected to Western blotting with anti-TRAIL antibodies, com-
ared with expression of beta-tubulin, and subjected to densitometric
nalysis.CR demonstrated no differences among the three studyroups. Moreover, no correlation was evident between
RNA level and soluble TRAIL concentrations.
ISCUSSION
n the current study, we demonstrate for the first time that
RAIL is expressed in atherosclerotic plaques from humans
nd atherosclerotic ApoE knockout mice. The control
onatherosclerotic vessels also exhibit TRAIL protein ex-
ression, although to a lesser extent, which is consistent
ith reports demonstrating its presence within smooth
uscle cells (15). Tumor necrosis factor-related apoptosis-
nducing ligand was found to colocalize with CD3 cells and
ith oxLDL by immunohistochemical staining. Moreover,
e showed that oxLDL but not its active derivatives (LPC)
an induce TRAIL mRNA and protein expression in
BMCs.
In different studies, oxLDL was shown to have proin-
ammatory and proatherogenic properties, that is, promot-
ng T cells and monocyte chemotaxis and adhesion and
nduction of proinflammatory genes (reviewed in references
to 3). It also has been suggested to trigger T-cell–
ependent autoimmune responses in the atherosclerotic
laques (4). These inflammatory reactions were proposed to
lay a critical role in atherosclerotic plaque formation,
rogression, and vulnerability. By demonstrating that
RAIL is colocalized with CD3 cells and oxLDL and is
nducible by oxLDL priming, it may be speculated that
RAIL has a role in controlling the balance between
roatherosclerotic and antiatherosclerotic programs within
he atheroma.
The rational for assuming a functional role for TRAIL in
he progression and destabilization of the atherosclerotic
laque stems from several observations. Tumor necrosis
actor-related apoptosis-inducing ligand was found to dis-
lay T-cell immunomodulatory properties (8,9,16). Studies
n animal models have shown that TRAIL affects growth of
cells and effector functions. Soluble active TRAIL nega-
ively regulates calcium influx through store-operated cal-
ium release-activated calcium channels, which is crucial to
ctivation of lymphocytes. Furthermore, soluble TRAIL
as shown to inhibit the production of interferon-gamma
nd IL4 and to block cell-cycle progression from G1 to S
hase and subsequent proliferation in human T cells
10,11,16). The neutralization of TRAIL receptors in
nimals caused exacerbation of autoimmune encephalomy-
litis (17) and type I diabetes mellitus (18), whereas soluble
RAIL levels correlated with the response in patients with
ultiple sclerosis to interferon-beta (19). An additional
eneficial property of TRAIL is its endothelial protective
roperties, which are related in part to nitric oxide genera-
ion (12,13). Dysfunctional endothelium and autoimmune
cells are thought to influence atherosclerosis initiation
nd progression (1–3), and their amelioration by TRAIL
ay thus bear antiatherogenic attributes in this context.
Tumor necrosis factor-related apoptosis-inducing ligand
i
t
e
t
d
a
d
i
s
n
t
P
s
t
T
p
p
s
w
c
a
m
i
g
l
p
p
t
W
r
o
i
u
t
e
n
u
a
C 
sient i
1023JACC Vol. 45, No. 7, 2005 Michowitz et al.
April 5, 2005:1018–24 TRAIL and Atherosclerosiss a transmembrane protein with an extracellular, carboxy-
erminal domain. Soluble TRAIL is generated through the
nzymatic cleavage of this extracellular domain. We found
hat soluble TRAIL levels in patients with ACS are
rastically reduced as compared with patients with stable
therosclerotic disease and individuals with normal coronary
isease. Interestingly, other members of the TNF superfam-
ly that were assayed (TNF-alpha and Fas-Ligand) in the
erum of the patients with stable and unstable angina did
ot differ between the groups, suggesting the results ob-
ained for soluble TRAIL were not of a “class effect.”
atients with ACS are a subgroup of patients with athero-
clerosis that are thought to display vulnerable plaques and
hus suffer clinical sequels due to vessel obstruction (5,6).
he significantly lower TRAIL levels in this group of
atients suggest a possible protective stabilizing role for this
rotein. Although this observation is speculative, it is
omewhat supported by the finding that TRAIL expression
as more robust in plaques with a vulnerable phenotype as
Table 1. Clinical Data of the Three Different
Acute Coronary
Syndrome
(n  40)
Men/women 34/6
Age (yrs) 61.2  14.8
LVEF (%) 49.6  10.8
NYHA-FC 4
CAD extent (n  vessels) 1.59  0.8
Past history
Previous MI, n (%) 14 (35)
Previous CABG, n (%) 3 (7.5)
Previous PTCA, n (%) 15 (37.5)
Previous TIA/CVA, n(%) 1 (2.5)
CRF† 6 (15)
Risk factors
Hypertension, n (%) 19 (47.5)
Diabetes, n (%) 8 (20)
Smoking
Current smoker, n (%) 21 (52.5)
Past smoker, n (%) 10 (25)
Hyperlipidemia, n (%) 27 (67.5)
Medications
Beta-blockers, n (%) 18 (45)
ACEI, n (%) 10 (25)
ARB, n (%) 1 (2.5)
Aspirin, n (%) 25 (62.5)
Clopidogrel, n (%) 4 (10)
Statins, n (%) 20 (50)
Calcium blocker, n (%) 4 (10)
Nitrates, n (%) 11 (27.5)
Diuretics, n (%) 5 (12.5)
Hypoglycemics, n (%) 2 (5)
Biochemistry
Soluble-TRAIL, pg/ml 238.6  199.3
CRP 12.2  16.8
Data are in number (range) or mean  SD. *Comparison onl
patients. †Defined as baseline creatinine above 1.5 mg/dl. ‡Ca
ACEI  angiotensin-converting enzyme inhibitors; ARB
graft; CAD  coronary artery disease; CRF  chronic renal
ejection function; MI  myocardial infarction; NYHA-F
percutaneous transluminal coronary angioplasty; TIA  tranompared with stable lesions. This finding may be related to cconsumption effect of TRAIL into the lesions that are
ore likely to be infiltrated by immune cells.
Interestingly, we found that TRAIL mRNA expression
n PBMCs was not different in the patients from the three
roups and that no significant correlation to soluble TRAIL
evels existed. These findings could suggest that the TRAIL
rotein may not be reduced in ACS because of diminished
roduction by circulatory T cells but rather consumed into
he plaque, as suggested after the results obtained with the
estern blotting assays. Recently, Nakajima et al. (20)
eported that the expression of TRAIL by flow cytometry
n peripheral lymphocytes in patients with acute myocardial
nfarction was increased when compared with healthy vol-
nteers. Unlike our study, TRAIL levels were evaluated in
he PMBCs of patients with established acute ST-segment
levation myocardial infarction in which cardiomyocyte
ecrosis was evident, whereas in our study most patients had
nstable angina. Moreover, the control patients were healthy
nd, therefore, their atherosclerosis burden was not similar and
ps of Patients: Univariate Analysis
table Angina
(n  28)
Normal Coronary
Arteries
(n  20) p Value
25/3 15/5 0.4‡
4.1  10.7 55.6  9.2 0.07
3.5  8.6 59.4  2.3 0.001
.46  0.63 1.15  0.48
2  0.9 0 (0) 0.12*‡
15 (53.5) 0 (0) 0.12*
8 (28.5) 0 (0) 0.08*‡
20 (71.4) 0 (0) 0.006*
2 (7) 1 (5) ‡
4 (14.2) 1 (5) ‡
16 (57.1) 8 (40) 0.5
12 (42.8) 1 (5) 0.007
12 (42.8) 5 (25) 0.12
6 (21.4) 4 (20) 0.89
24 (85.7) 8 (40) 0.004
22 (78.5) 3 (15) 0.0001
14 (50) 5 (25) 0.07
1 (3.5) 0 (0) 0.7‡
22 (78.5) 9 (45) 0.057
7 (25) 0 (0) 0.03‡
22 (78.5) 4 (20) 0.0003
11 (39.2) 2 (10) 0.006
11 (39.2) 0 (0) 0.007
8 (28.5) 2 (10) 0.15‡
5 (17.8) 0 (0) 0.112‡
2.7  349.1 637  281.2 0.0001
8.2  16.7 4.9  5.1 0.19
een acute coronary syndrome (ACS) and stable angina pectoris
al variables that were analyzed by the Fisher exact test.
giotensin receptor blocker; CABG  coronary artery bypass
; CVA  cerebrovascular accident; LVEF  left ventricular
New York Heart Association functional class; PTCA 
schemic attack.Grou
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failureould have initially confounded the interpretation of the data.
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TRAIL and Atherosclerosis April 5, 2005:1018–24or this purpose and to avoid the effect of plaque burden, we
hose patients with ACS and stable lesions that had a similar
xtent of coronary affliction by atherosclerosis.
C-reactive protein, a nonspecific “acute-phase” protein, is
known marker of acute vascular events (21) and is closely
ssociated with plaque instability and oxidative stress (22).
oluble TRAIL levels were found to be negatively corre-
ated with hsCRP concentrations, supporting a possible
rotective role of TRAIL in atherosclerosis and plaque
nstability.
onclusions. We demonstrated that TRAIL is expressed
n atherosclerotic plaques and is colocalized with CD3 cells
nd oxLDL. We also demonstrated that TRAIL is induced
n PBMCs by oxLDL. In ACS, the levels of soluble
RAIL are reduced and correlate negatively with the
roinflammatory acute-phase reactant CRP, whereas ex-
ression of TRAIL is significantly higher in plaques with a
ulnerable as compared with a stable phenotype. If further
alidated, in vivo TRAIL could have a role as a protective
igure 4. Soluble tumor necrosis factor-related apoptosis-inducing ligand
sTRAIL) protein concentrations and correlation with C-reactive protein.
A) Sera from patients with acute coronary syndrome (ACS), stable angina
ectoris, or NCA were assayed for sTRAIL levels using enzyme-linked
mmunosorbent assay as described in the Methods section. (B) Correlation
f TRAIL serum levels with concentrations of high-sensitivity C-reactive
rotein (hsCRP) (described in the Methods section) is shown.gent in patients with ACS.eprint requests and correspondence: Dr. Jacob George, De-
artment of Cardiology, Tel Aviv Sourasky Medical Center, Tel
viv, Israel. E-mail: jacobg@post.tau.ac.il.
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